Rare and Autoimmune Diseases: TCR Treg Therapy

Baudax Bio is a biotechnology company focused on developing and commercializing innovative products for rare and autoimmune diseases.

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers. Our pipeline includes clinical and early-stage product candidates

About Us

Our Innovative Portfolio & Pipeline

Our product candidate pipeline includes early-stage product candidates, including recently acquired TCR TReg platform and two novel neuromuscular blocking agents (NMBAs) and a related proprietary chemical reversal agent.

Product Portfolio

Latest News

Baudax Bio Announces Corporate Update

View Press Release

Baudax Bio Announces Corporate Update

View Press Release

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today